Home
About Us
Introduction
R&D and Production
Platform
Social Responsibility
Products
GLP-1 Side Chains
AEEA
AEEA-AEEA
Boc-AEEA-OH
Fmoc-AEEA-OH
tBuO-C20-Glu-OtBu
tBuO-C20-Glu(OSu)-OtBu
Peptide Intermediates
Fmoc-His-Aib-OH
Fmoc-Ile-Aib-OH
Fmoc-Tyr(tBu)-Aib-OH
Fmoc-Glu(OtBu)-Aib-OH
Fmoc-His(Fmoc)-Aib-OH
Fmoc-His(Fmoc)-Aib-OSu
Tirzepatide Fragments
CAS:2682040-93-1
CAS:3034670-52-2
CAS:1262308-37-1
CAS:2461524-68-3
CAS:2656383-24-1
CAS:2656383-25-2
API & Excipients
Tirzepatide
Semaglutide
Salcaprozate Sodium (SNAC）
Cosmetic Peptides
Oligopeptide-1
NonaPeptide-1
Copper Tripeptide-1
Acetyl Hexapeptide-8
Palmitoyl Tripeptide-1
Decarboxy Carnosine HCl
Active Ingredients
Bisyne<sup>®</sup>
CG HPR
CG Chroman'6<sup>®</sup>
CG Retinol
CG HP100
Adsolue <sup>®</sup> TPGS
News
Events
Industry News
Contact
Search
marketing@congenpharm.com
The Vital Role of Fatty Acid Side Chains in Long-Acting GLP-1 Receptor Agonists
2025-08-18
Raynovent Initiates Phase III Trials for GLP-1R/GIPR Dual Agonist, Challenging Semaglutide
2025-08-08
Liquid Phase Peptide Synthesis (LPPS): Cases & Strategic Advantages-CongenPharma-Patented Technology
2025-08-07
Shiseido’s New Research! Surprising New Benefits of Retinol?
Unlocking the Potential of GLP-1 Sidechain Intermediates in CDMO Development
2025-08-06
Unlocking New Avenues: The Emergence of GLP-1 Side Chain Production and Supply
2025-08-05
